In the current API industry, embracing three major trends helps enterprises gain a firm foothold and achieve steady progress.
◆ Continuously enriching the product pipeline through R&D can enhance market competitiveness to a certain extent. Take Minova Pharmaceutical as an example. The company has laid out its business in fields such as antihypertensive, hypoglycemic and anti-infective drugs. With a continuously enriched product pipeline, it has formed a product portfolio in the chronic disease sector, achieving a marked improvement in market competitiveness.
◆ Integration of API + formulation can greatly reduce costs and has become a key development direction for API and generic pharmaceutical enterprises. Leading API companies including Huahai Pharmaceutical and Stellite Pharmaceutical have extended their business downstream into finished formulations by leveraging their API advantages, capturing market share with superior cost performance.
◆ Specialty API enterprises expand into CMO/CDMO businesses to amplify their inherent strengths. China's CDMO industry is currently in a period of rapid development, enabling many enterprises to complete strategic transformation swiftly. For instance, Apeloa Pharmaceutical has shifted its core business focus to the CDMO sector, driving a substantial increase in revenue from related businesses.
In summary, the API industry presents growing investment opportunities on the main track from now on, and will remain an optimal choice for the medium and long-term development of the pharmaceutical industry. For relevant enterprises, whether they can seize opportunities and forge ahead against challenges has become the decisive key to future growth.
